The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
Open accessAbstract
BACKGROUND: A recent randomized phase II trial evaluated stereotactic ablative radiotherapy (SABR) in a group of patients with a small burden of oligometastatic disease (mostly with 1-3 metastatic lesions), and found that SABR was associated with a significant improvement in progression-free survival and a trend to an overall survival benefit, supporting progression to phase III randomized trials. METHODS: Two hundred and ninety-seven patients will be randomized in a 1:2 ratio between the control arm (consisting of standard of care [SOC] palliative-intent treatments), and the SABR arm (consisting of SOC treatment + SABR to all sites of known disease). Randomization will be stratified by two factors: histology (prostate, breast, or renal vs. all others), and disease-free interval (defined as time from diagnosis of primary tumor until first detection of the metastases being treated on this trial; divided as ≤2 vs. > 2 years). The primary endpoint is overall survival, and secondary endpoints include progression-free survival, cost effectiveness, time to development of new metastatic lesions, quality of life (QoL), and toxicity. Translational endpoints include assessment of circulating tumor cells, cell-free DNA, and tumor tissue as prognostic and predictive markers, including assessment of immunological predictors of response and long-term survival. DISCUSSION: This study will provide an assessment of the impact of SABR on survival, QoL, and cost effectiveness to determine if long-term survival can be achieved for selected patients with 1-3 oligometastatic lesions. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03862911. Date of registration: March 5, 2019.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417
Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases
Pastorino, U., Buyse, M., Friedel, G., Ginsberg, R. J., Girard, P., Goldstraw, P., Johnston, M., McCormack, P., Pass, H., & Putnam, J. B. (1997) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(97)70397-0 · Cited by 1,529
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
Rusthoven, K. E., Kavanagh, B. D., Burri, S. H., Chen, C., Cardenes, H., Chidel, M. A., Pugh, T. J., Kane, M., Gaspar, L. E., & Schefter, T. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6386 · Cited by 1,082
Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline
Lutz, S., Berk, L., Chang, E., Chow, E., Hahn, C., Hoskin, P., Howell, D., Konski, A., Kachnic, L., Lo, S., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.11.026 · Cited by 863
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
Rusthoven, K. E., Kavanagh, B. D., Cardenes, H., Stieber, V. W., Burri, S. H., Feigenberg, S. J., Chidel, M. A., Pugh, T. J., Franklin, W., Kane, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6329 · Cited by 805
Cox, B. W., Spratt, D. E., Lovelock, M., Bilsky, M. H., Lis, E., Ryu, S., Sheehan, J., Gerszten, P. C., Chang, E., Gibbs, I., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.009 · Cited by 609
Pfannschmidt, J., Dienemann, H., & Hoffmann, H. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.02.093 · Cited by 557
An Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation Oncology
Timmerman, R. D. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.04.001 · Cited by 478
Ruers, T., Punt, C., Van Coevorden, F., Pierie, J. P. E. N., Borel-Rinkes, I., Ledermann, J. A., Poston, G., Bechstein, W., Lentz, M. A., Mauer, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds053 · Cited by 442
Cited by
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32487-5 · Cited by 1,857
Self-citationOst, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Palma, D. A., Olson, R., Harrow, S., Gaede, S., Louie, A. V., Haasbeek, C., Mulroy, L., Lock, M., Rodrigues, G. B., Yaremko, B. P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00818 · Cited by 1,300
Self-citationGerstberger, S., Jiang, Q., & Ganesh, K. (2023) · Cell · doi:10.1016/j.cell.2023.03.003 · Cited by 913
Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., Congedo, M. T., Gomez, D. R., Wright, G. M., Melloni, G., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.04.003 · Cited by 435
Self-citation
Metadata
- Authors
- Palma, D. A., Haasbeek, C. J. A., Rodrigues, G. B., Dahele, M., Lock, M., Yaremko, B., Olson, R., Liu, M., Panarotto, J., Griffioen, G., Gaede, S., Slotman, B., & Senan, S.
- Venue
- BMC Cancer
- Published
- 2012-07-23
- Volume
- 12
- Issue
- 1
- Pages
- 305-305
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2131110909
- Cited by
- 302
- References
- 26
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. https://app.cochat.ai/papers/10.1186/1471-2407-12-305
- The paper
- Palma, D. A., Haasbeek, C. J. A., Rodrigues, G. B., Dahele, M., Lock, M., Yaremko, B., Olson, R., Liu, M., Panarotto, J., Griffioen, G., Gaede, S., Slotman, B., & Senan, S. (2012). Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. BMC Cancer. https://doi.org/10.1186/1471-2407-12-305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.